logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9896514 B1

PDFFull Text
Date of Patent:
Feb. 20, 2018

Filed:

Apr. 15, 2016

[object object]

Applicant:

The Secretary of State for Health, London, GB;

Inventors:

Clifford Shone, Salisbury, GB;

April Roberts, Salisbury, GB;

Michael Maynard-Smith, Salisbury, GB;

Assignee:

The Secretary of State for Health, London, GB;

Attorney:

Christensen O'Connor Johnson Kindness PLLC

Primary Examiner:

Padmavathi Baskar

Int. Cl.
CPC ...
C07K 16/40 (2006.01); C07K 14/33 (2006.01); A61K 39/40 (2006.01); A61K 45/06 (2006.01); C12N 9/10 (2006.01); A61K 39/08 (2006.01); G01N 33/573 (2006.01); G01N 33/569 (2006.01); C07K 16/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 39/08 (2013.01); A61K 39/40 (2013.01); A61K 45/06 (2013.01); C07K 14/33 (2013.01); C07K 16/1282 (2013.01); C12N 9/1051 (2013.01); G01N 33/56911 (2013.01); G01N 33/573 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/55566 (2013.01); C07K 2317/21 (2013.01); C07K 2317/54 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); G01N 2333/91097 (2013.01); G01N 2469/10 (2013.01); G01N 2469/20 (2013.01);
Abstract

The present invention relates to recombinantantigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of aToxin A sequence or aToxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 ofToxin A and/or residues 1853-2366 of aToxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/treatment/suppression ofinfection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

Find Patent Forward Citations

Loading…